GlassScriptPhysician profile
Jay Nguyen
NPI 1780324798
$8,196.74
in general payments reported to CMS, 2019-2025
24 companies · $3,978 in 2025
The $3,978 reported for 2025 was more than what 88% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $448 · 2024: $3,771 · 2025: $3,978.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,035 · Education: $99.00 · Travel and Lodging: $62.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,035.24 |
| Education | $99.00 |
| Travel and Lodging | $62.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $906.33 | 2024-2025 | |
| Janssen Biotech, INC. | $786.25 | 2024-2025 | Tremfya |
| Lilly USA, LLC | $736.22 | 2024-2025 | Ebglyss, Olumiant, Taltz |
| Sun Pharmaceutical Industries INC. | $687.65 | 2023-2025 | |
| Ucb, INC. | $552.62 | 2023-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $526.93 | 2024-2025 | Dupixent, Libtayo |
| Dermavant Sciences, INC. | $444.62 | 2024 | Vtama |
| Galderma Laboratories, L.P. | $437.79 | 2024-2025 | Nemluvio |
| Novartis Pharmaceuticals Corporation | $431.33 | 2023-2025 | |
| Pfizer INC. | $424.99 | 2024-2025 | |
| Arcutis Biotherapeutics, INC. | $308.77 | 2024-2025 | Zoryve |
| Amgen INC. | $272.27 | 2024-2025 | Otezla, Otezla |
| Genzyme Corporation | $258.77 | 2024-2025 | |
| Incyte Corporation | $236.96 | 2023-2025 | Opzelura |
| Leo Pharma INC. | $233.73 | 2023-2024 | Adbry |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $207.46 | 2025 | Tremfya |
| Organon LLC | $160.07 | 2025 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $134.48 | 2024-2025 | Sotyktu |
| Botanix Sb INC | $127.91 | 2025 | Sofdra |
| Kerecis Limited | $127.31 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Verrica Pharmaceuticals INC. | $111.08 | 2024 | Ycanth |
| Acera Surgical, INC. | $31.76 | 2024 | Restrata Wound Matrix |
| Almirall LLC | $31.50 | 2024 | Klisyri |
| Paratek Pharmaceuticals, INC. | $19.94 | 2025 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.